Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review

Yuichiro Ohya, Noriko Makihara, Kayo Wakisaka, Takao Morita, Tetsuro Ago, Takanari Kitazono, Hitonori Takaba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab. The thrombolytic therapy following the use of idarucizumab significantly improved the patient's neurological symptoms without hemorrhagic complications, although acute arterial occlusion of the right lower limb was found during the clinical course.

Original languageEnglish
Pages (from-to)e128-e131
JournalJournal of Stroke and Cerebrovascular Diseases
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Thrombolytic Therapy
Stroke
Tissue Plasminogen Activator
Antidotes
Middle Cerebral Artery
National Institutes of Health (U.S.)
Atrial Fibrillation
Lower Extremity
idarucizumab
Dabigatran
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab : Case Report and Literature Review. / Ohya, Yuichiro; Makihara, Noriko; Wakisaka, Kayo; Morita, Takao; Ago, Tetsuro; Kitazono, Takanari; Takaba, Hitonori.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 27, No. 7, 01.07.2018, p. e128-e131.

Research output: Contribution to journalArticle

@article{f1cdf9d0ea5a4af4aa2fd1e08d8dce00,
title = "Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review",
abstract = "Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab. The thrombolytic therapy following the use of idarucizumab significantly improved the patient's neurological symptoms without hemorrhagic complications, although acute arterial occlusion of the right lower limb was found during the clinical course.",
author = "Yuichiro Ohya and Noriko Makihara and Kayo Wakisaka and Takao Morita and Tetsuro Ago and Takanari Kitazono and Hitonori Takaba",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.jstrokecerebrovasdis.2018.02.025",
language = "English",
volume = "27",
pages = "e128--e131",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab

T2 - Case Report and Literature Review

AU - Ohya, Yuichiro

AU - Makihara, Noriko

AU - Wakisaka, Kayo

AU - Morita, Takao

AU - Ago, Tetsuro

AU - Kitazono, Takanari

AU - Takaba, Hitonori

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab. The thrombolytic therapy following the use of idarucizumab significantly improved the patient's neurological symptoms without hemorrhagic complications, although acute arterial occlusion of the right lower limb was found during the clinical course.

AB - Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab. The thrombolytic therapy following the use of idarucizumab significantly improved the patient's neurological symptoms without hemorrhagic complications, although acute arterial occlusion of the right lower limb was found during the clinical course.

UR - http://www.scopus.com/inward/record.url?scp=85043979981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043979981&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2018.02.025

DO - 10.1016/j.jstrokecerebrovasdis.2018.02.025

M3 - Article

C2 - 29555397

AN - SCOPUS:85043979981

VL - 27

SP - e128-e131

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 7

ER -